Sunday, December 21, 2014

Amarantus in second closing of Series E preferred

Amarantus in second closing of Series E preferred

December 19, 2014 by · Leave a Comment 

Tweet Amarantus BioScience Holdings (OTCQB:AMBS) has entered into definitive agreements to raise an additional $2-million under its previously announced transaction to issue Series E preferred stock, bringing the total capital raised to $5-million. “In recent months, we have been working towards further strengthening our balance sheet, and I am very pleased to have the ability […]

Medifocus receives two Canadian patents

Medifocus receives two Canadian patents

December 15, 2014 by · Leave a Comment 

Tweet Medifocus (OTCQX:MDFZF; TSX-V:MFS) has obtained two newly allowed Canadian patents covering its platform technology for the treatment of breast cancer. The titles of the patents are “Thermotherapy Method for Treatment and Prevention of Breast Cancer” and the “Method for Improved Safety in Externally Focused Microwave Thermotherapy for Treating Breast Cancer.” A major embodiment of […]

Cantor upgrades Sunesis Pharma to buy

Cantor upgrades Sunesis Pharma to buy

December 10, 2014 by · Leave a Comment 

Tweet Cantor Fitzgerald has upgraded Sunesis Pharmaceuticals (NASDAQ:SNSS) to “buy” and raised its price target to $4 from $2 ahead of an FDA meeting in early 2015. The stock closed at $2.31 on Tuesday. “With the full VALOR dataset now in the public domain (presented as an ASH late-breaker on Dec. 9), we think expectations […]

WB starts Revance Therapeutics at outperform

WB starts Revance Therapeutics at outperform

December 9, 2014 by · Leave a Comment 

Tweet William Blair has launched coverage of Revance Therapeutics (NASDAQ:RVNC) with an “outperform” rating and $35 price target. The stock closed at $17.42 on Monday. Revance is developing two highly differentiated next-generation botulinum toxin products, RT001 and RT002, using its TransMTS technology. Analyst Tim Lugo writes that RT001 is the more controversial of the two. […]

Nuvo Research to release Phase 2 WF10 data in Q1

Nuvo Research to release Phase 2 WF10 data in Q1

December 2, 2014 by · Leave a Comment 

Tweet Nuvo Research (TSX:NRI) plans to release, in the first quarter of 2015, the results of a confirmatory Phase 2 study for a potential blockbuster allergic rhinitis drug, WF10, which could be a game-changing treatment for moderate-to-severe allergies. “We are targeting a large unmet medical need among some 10 million people in the U.S. who […]

Knight sells priority review voucher for $125-million

Knight sells priority review voucher for $125-million

November 19, 2014 by · Leave a Comment 

Tweet Knight Therapeutics (TSX:GUD) has sold its neglected tropical disease priority review voucher (PRV) to Gilead Sciences for $125-million. “We are thrilled to successfully transfer our priority review voucher in expectation that this will encourage others to invest in R&D for neglected tropical diseases for the benefit of humanity,” Jonathan Goodman, president and CEO of […]

Tandem takes consumer device approach to insulin pumps

Tandem takes consumer device approach to insulin pumps

November 18, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=qMfQNC0MqbI&list=PLaVPFQzKqgRmCoJ4T6oNF7v3EWcnDCobu’]

Tweet Tandem Diabetes (NASDAQ:TNDM), which now markets the popular t:slim Insulin Pump for people with Type 1 diabetes and has two new pumps awaiting FDA clearance, has taken a unique consumer-focused approach to the design of its products. “When we started the company, we had to figure out why only 27% of people with Type […]

rEVO Biologics spearheading preeclampsia treatment

rEVO Biologics spearheading preeclampsia treatment

November 11, 2014 by · Leave a Comment 

Tweet Closely held rEVO Biologics is enrolling patients in a Phase 3 clinical trial of its ATryn recombinant human antithrombin for the treatment of early-onset preeclampsia, with top-line data expected in the second quarter of 2016. “This is a potentially life threatening disorder of pregnancy and a devastating unmet medical need,” Yann Echelard, president and […]

Aeterna Zentaris gets CRL on Macrilen

Aeterna Zentaris gets CRL on Macrilen

November 6, 2014 by · Leave a Comment 

Tweet Aeterna Zentaris (NASDAQ:AEZS; TSX:AEZ) has received a complete response letter (CRL) from the FDA for its NDA for Macrilen (macimorelin), a novel orally active ghrelin agonist, for use in evaluating adult growth hormone deficiency (AGHD). Based on its review, the FDA has determined that the NDA cannot be approved in its present form. The CRL said […]

AD focus shifts to treating agitation/aggression

AD focus shifts to treating agitation/aggression

October 28, 2014 by · Leave a Comment 

Tweet After years of fruitless search for new therapies to slow the deadly progression of Alzheimer’s disease (AD), researchers are having more success with experimental treatments for the neuropsychiatric symptoms associated with AD, such as agitation and aggression. A case in point is Avanir Pharmaceuticals (NASDAQ:AVNR), which reported positive results in mid-September from a Phase […]

Next Page »

Email Newsletters with Constant Contact
Google+